At present, intravitreal injection of an anti-vascular endothelial growth factor (VEGF) agent is the first line treatment for neovascular age-related macular degeneration (nAMD), and this strategy reportedly improves and maintains visual acuity in affected patients1. Here, VEGFA is linked to wet macular degeneration.